Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
24 07 2020
Historique:
received: 06 06 2020
revised: 09 07 2020
accepted: 11 07 2020
entrez: 30 7 2020
pubmed: 30 7 2020
medline: 13 3 2021
Statut: epublish

Résumé

Cervical dystonia (CD) is a neurological movement disorder characterized by sustained involuntary muscle contractions. First-line therapy for CD is intramuscular injections of botulinum neurotoxin (e.g., abobotulinumtoxinA) into the affected muscles. The objective of this systematic literature review is to assess the clinical evidence regarding the effects of abobotulinumtoxinA for treatment of CD in studies of safety, efficacy, patient-reported outcomes, and economic outcomes. Using comprehensive electronic medical literature databases, a search strategy was developed using a combination of Medical Subject Heading terms and keywords. Results were reviewed by two independent reviewers who rated the level of evidence. The search yielded 263 publications, of which 232 were excluded for being duplicate publications, not meeting the selection criteria, or failing to meet predefined eligibility criteria, leaving a total of 31 articles. Clinical efficacy, patient-reported outcomes, and safety data were in 6 placebo-controlled trials (8 articles), 6 active-controlled trials, and 16 observational studies (17 articles). Data on health economic outcomes were provided in one of the clinical trials, in two of the observational studies, and in one specific cost-analysis publication. This review demonstrated that the routine use of abobotulinumtoxinA in CD is well-established, effective, and generally well-tolerated, with a relatively low cost of treatment.

Identifiants

pubmed: 32722133
pii: toxins12080470
doi: 10.3390/toxins12080470
pmc: PMC7472382
pii:
doi:

Substances chimiques

Neuromuscular Agents 0
Botulinum Toxins, Type A EC 3.4.24.69
abobotulinumtoxinA EC 3.4.24.69

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ipsen Biopharmaceuticals Canada, Inc., Mississauga, ON, Canada
ID : n/a
Pays : International

Références

Neurology. 2008 May 6;70(19):1699-706
pubmed: 18458230
Mov Disord. 2015 Feb;30(2):206-13
pubmed: 25476727
J Neurol. 1999 Apr;246(4):265-74
pubmed: 10367694
BMJ Open. 2011 Jan 1;1(2):e000196
pubmed: 22021883
J Neurol Sci. 2017 May 15;376:84-90
pubmed: 28431634
J Neurol. 2001 Dec;248(12):1073-8
pubmed: 12013585
Mov Disord. 2004 Mar;19(3):303-8
pubmed: 15022184
Clin Neuropharmacol. 2015 Nov-Dec;38(6):221-6
pubmed: 26536017
Clin Neuropharmacol. 2000 Jul-Aug;23(4):203-7
pubmed: 11020124
Clinicoecon Outcomes Res. 2017 Apr 15;9:211-229
pubmed: 28458568
Eur Neurol. 2002;47(4):214-21
pubmed: 12037435
J Neurol. 2015 Oct;262(10):2201-13
pubmed: 25877834
Int J Neurosci. 2012 Jul;122(7):354-7
pubmed: 22329596
Mov Disord. 2013 Jun 15;28(7):926-43
pubmed: 23893450
J Manag Care Spec Pharm. 2015 Oct;21(10):854-60
pubmed: 26402386
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Mov Disord. 2016 Nov;31(11):1649-1657
pubmed: 27653448
Muscle Nerve. 1995 Jul;18(7):720-9
pubmed: 7783762
Mov Disord. 2005 Aug;20(8):937-44
pubmed: 15810022
Neurotox Res. 2017 Aug;32(2):291-300
pubmed: 28478527
J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):13-7
pubmed: 9436721
Clin Neuropharmacol. 2012 Nov-Dec;35(6):278-82
pubmed: 23123690
J Neural Transm (Vienna). 2014 May;121(5):513-9
pubmed: 24311063
Tremor Other Hyperkinet Mov (N Y). 2013 Nov 04;3:
pubmed: 24255801
Parkinsonism Relat Disord. 2010 Jun;16(5):316-23
pubmed: 20359934
Neurol Res. 2009 Jun;31(5):463-6
pubmed: 19278576
Clin Neuropharmacol. 1997 Feb;20(1):42-8
pubmed: 9037572
Int J Neurosci. 2018 Jul;128(7):619-626
pubmed: 29343142
Exp Neurol. 2001 Mar;168(1):162-70
pubmed: 11170731
J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):6-12
pubmed: 9436720
BMJ Open. 2012 Jun 14;2(3):
pubmed: 22700836
Mov Disord. 2005 Jul;20(7):783-91
pubmed: 15736159
J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):459-62
pubmed: 11909903
J Neural Transm (Vienna). 2013 Mar;120(3):487-96
pubmed: 22899277
BMJ Open. 2013 Apr 18;3(4):
pubmed: 23604344
Pharmacoeconomics. 1997 Dec;12(6):695-706
pubmed: 10175981
BMJ Open. 2014 Oct 16;4(10):e005150
pubmed: 25324317

Auteurs

Alfonso Fasano (A)

Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON M5T2S8, Canada.
Division of Neurology, University of Toronto, Toronto, ON M5S 3H2, Canada.
Krembil Brain Institute, Toronto, ON M5T 1M8, Canada.

Vijayashankar Paramanandam (V)

Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON M5T2S8, Canada.
Division of Neurology, University of Toronto, Toronto, ON M5S 3H2, Canada.

Mandar Jog (M)

Lawson Health Research Institute, London, ON N6A 4V2, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH